Difference between revisions of "Template:Hormone levels with medroxyprogesterone acetate"

From blackwiki
Jump to navigation Jump to search
imported>Mikeblas
(remove unused reference name to avoid duplication at transclusion)
imported>Monkbot
m (Task 18a (cosmetic) (manual): eval 5 templates: del empty params (3×); hyphenate params (1×);)
 
Line 7: Line 7:
 
| File:Levels of medroxyprogesterone acetate with 2.5 or 5 mg per day oral medroxyprogesterone acetate in postmenopausal women.png | MPA levels with 2.5 or 5 mg/day [[oral administration|oral]] MPA in combination with 1 or 2&nbsp;mg/day [[estradiol valerate]] ([[Indivina]]) in postmenopausal women.<ref>{{cite journal|last1=Järvinen|first1=Asko|last2=Kainulainen|first2=Petri|last3=Nissilä|first3=Minna|last4=Nikkanen|first4=Hanna|last5=Kela|first5=Marjo|title=Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women|journal=Maturitas|volume=47|issue=3|year=2004|pages=209–217|issn=03785122|doi=10.1016/j.maturitas.2003.01.001}}</ref>
 
| File:Levels of medroxyprogesterone acetate with 2.5 or 5 mg per day oral medroxyprogesterone acetate in postmenopausal women.png | MPA levels with 2.5 or 5 mg/day [[oral administration|oral]] MPA in combination with 1 or 2&nbsp;mg/day [[estradiol valerate]] ([[Indivina]]) in postmenopausal women.<ref>{{cite journal|last1=Järvinen|first1=Asko|last2=Kainulainen|first2=Petri|last3=Nissilä|first3=Minna|last4=Nikkanen|first4=Hanna|last5=Kela|first5=Marjo|title=Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women|journal=Maturitas|volume=47|issue=3|year=2004|pages=209–217|issn=03785122|doi=10.1016/j.maturitas.2003.01.001}}</ref>
  
| File:Medroxyprogesterone acetate levels after a single 150 mg intramuscular injection of medroxyprogesterone acetate in women.png | MPA levels after a single 150&nbsp;mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986">{{cite book|last1=Goebelsmann|first1=Uwe|chapter=Pharmacokinetics of Contraceptive Steroids in Humans|editor1=A. T. Gregoire|editor2=Richard P. Blye|title=Contraceptive Steroids: Pharmacology and Safety|chapter-url=https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67|date=1986|publisher=Springer Science & Business Media|isbn=978-1-4613-2241-2|pages=67–111|doi=10.1007/978-1-4613-2241-2_4}}</ref><ref name="pmid833262">{{cite journal | vauthors = Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR | title = Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA | journal = J. Clin. Endocrinol. Metab. | volume = 44 | issue = 1 | pages = 32–8 | date = January 1977 | pmid = 833262 | doi = 10.1210/jcem-44-1-32 | url = }}</ref>
+
| File:Medroxyprogesterone acetate levels after a single 150 mg intramuscular injection of medroxyprogesterone acetate in women.png | MPA levels after a single 150&nbsp;mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986">{{cite book|last1=Goebelsmann|first1=Uwe|chapter=Pharmacokinetics of Contraceptive Steroids in Humans|editor1=A. T. Gregoire|editor2=Richard P. Blye|title=Contraceptive Steroids: Pharmacology and Safety|chapter-url=https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67|date=1986|publisher=Springer Science & Business Media|isbn=978-1-4613-2241-2|pages=67–111|doi=10.1007/978-1-4613-2241-2_4}}</ref><ref name="pmid833262">{{cite journal | vauthors = Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR | title = Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA | journal = J. Clin. Endocrinol. Metab. | volume = 44 | issue = 1 | pages = 32–8 | date = January 1977 | pmid = 833262 | doi = 10.1210/jcem-44-1-32 }}</ref>
  
| File:Medroxyprogesterone acetate levels after a single intramuscular injection of different doses of medroxyprogesterone acetate in women.png | MPA levels after a single 25 to 150&nbsp;mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986" /><ref name="pmid6451351">{{cite journal | vauthors = Fotherby K, Koetsawang S, Mathrubutham M | title = Pharmacokinetic study of different doses of Depo Provera | journal = Contraception | volume = 22 | issue = 5 | pages = 527–36 | date = November 1980 | pmid = 6451351 | doi = 10.1016/0010-7824(80)90105-5 | url = }}</ref>
+
| File:Medroxyprogesterone acetate levels after a single intramuscular injection of different doses of medroxyprogesterone acetate in women.png | MPA levels after a single 25 to 150&nbsp;mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986" /><ref name="pmid6451351">{{cite journal | vauthors = Fotherby K, Koetsawang S, Mathrubutham M | title = Pharmacokinetic study of different doses of Depo Provera | journal = Contraception | volume = 22 | issue = 5 | pages = 527–36 | date = November 1980 | pmid = 6451351 | doi = 10.1016/0010-7824(80)90105-5 }}</ref>
  
| File:Medroxyprogesterone acetate levels with a subcutaneous injection of 104 mg medroxyprogesterone acetate in women.png | MPA levels after a single 104&nbsp;mg [[subcutaneous injection]] of MPA (Depo-SubQ Provera) in [[aqueous suspension]] in women.<ref name="DepoSubQProveraLabel">{{cite web|title=depo-subQ Provera|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf|website=FDA|accessdate=31 March 2018|date=2017|df=}}</ref>
+
| File:Medroxyprogesterone acetate levels with a subcutaneous injection of 104 mg medroxyprogesterone acetate in women.png | MPA levels after a single 104&nbsp;mg [[subcutaneous injection]] of MPA (Depo-SubQ Provera) in [[aqueous suspension]] in women.<ref name="DepoSubQProveraLabel">{{cite web|title=depo-subQ Provera|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf|website=FDA|access-date=31 March 2018|date=2017}}</ref>
  
 
}}}}<!--
 
}}}}<!--

Latest revision as of 15:20, 16 December 2020

Template documentation

See also

References

  1. Järvinen, Asko; Kainulainen, Petri; Nissilä, Minna; Nikkanen, Hanna; Kela, Marjo (2004). "Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women". Maturitas. 47 (3): 209–217. doi:10.1016/j.maturitas.2003.01.001. ISSN 0378-5122.
  2. 2.0 2.1 Goebelsmann, Uwe (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In A. T. Gregoire; Richard P. Blye (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
  3. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR (January 1977). "Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA". J. Clin. Endocrinol. Metab. 44 (1): 32–8. doi:10.1210/jcem-44-1-32. PMID 833262.
  4. Fotherby K, Koetsawang S, Mathrubutham M (November 1980). "Pharmacokinetic study of different doses of Depo Provera". Contraception. 22 (5): 527–36. doi:10.1016/0010-7824(80)90105-5. PMID 6451351.
  5. "depo-subQ Provera" (PDF). FDA. 2017. Retrieved 31 March 2018.